160 related articles for article (PubMed ID: 38449377)
1. A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.
Harris JP; Park J; Ku E; Seyedin S; Stitzlein R; Goldin A; Chen WP; McLaren C; Chen AM; Chow W
Cancer Control; 2024; 31():10732748241237331. PubMed ID: 38449377
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
Guan J; Sun K; Guerrero CA; Zheng J; Xu Y; Mathur S; Teh BS; Farach A; Zhang J; Butler E; Pan PY; Zsigmond E; Mei Z; Mejia J; Chen SH; Chang JC; Bernicker EH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1531-1540. PubMed ID: 37625523
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
5. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC; Polley MY; Bhave SR; Redler G; Pitroda SP; Luke JJ; Chmura SJ
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):189-195. PubMed ID: 32569799
[TBL] [Abstract][Full Text] [Related]
6. Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction.
Belluomini L; Dionisi V; Palmerio S; Vincenzi S; Avancini A; Casali M; Riva ST; Menis J; Mazzarotto R; Pilotto S; Milella M
Clin Lung Cancer; 2022 May; 23(3):e269-e272. PubMed ID: 34470722
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2022 Mar; 23(3):e105-e115. PubMed ID: 35240087
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.
le Guevelou J; Debaigt C; Saada-Bouzid E; Viotti J; Khalladi N; Thibouw D; Penel N; Sunyach MP; Moureau-Zabotto L; Benchalal M; Veresezan O; Ducassou A; le Pechoux C; Jolnerovski M; Bazille C; Vaur D; Escande A; Serre R; Lovera C; Thariat J
BMJ Open; 2020 Sep; 10(9):e038391. PubMed ID: 32967883
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma.
Callaghan CM; Seyedin SN; Mohiuddin IH; Hawkes KL; Petronek MS; Anderson CM; Buatti JM; Milhem MM; Monga V; Allen BG
Radiat Res; 2020 Aug; 194(2):124-132. PubMed ID: 32845986
[TBL] [Abstract][Full Text] [Related]
10. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ; Lemons JM; Karrison TG; Pitroda SP; Melotek JM; Zha Y; Al-Hallaq HA; Arina A; Khodarev NN; Janisch L; Chang P; Patel JD; Fleming GF; Moroney J; Sharma MR; White JR; Ratain MJ; Gajewski TF; Weichselbaum RR; Chmura SJ
J Clin Oncol; 2018 Jun; 36(16):1611-1618. PubMed ID: 29437535
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy.
Gutkin PM; Gore E; Charlson J; Neilson JC; Johnstone C; King DM; Hackbarth DA; Wooldridge A; Mannem R; Bedi M
Radiat Oncol; 2023 Mar; 18(1):42. PubMed ID: 36859309
[TBL] [Abstract][Full Text] [Related]
12. A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report.
Ni J; Yang L; Zhu H; Chu M; Zhang C; Zhao W; Yang M; Xu X; Zheng E; Jiang X; Li R; Zhao G
Ann Palliat Med; 2021 Apr; 10(4):4999-5009. PubMed ID: 33966436
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B; Beardslee T; Khuri FR; Curran W; Lonial S; Waller EK; Ramalingam S; Owonikoko TK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428583
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.
Sundahl N; Vandekerkhove G; Decaestecker K; Meireson A; De Visschere P; Fonteyne V; De Maeseneer D; Reynders D; Goetghebeur E; Van Dorpe J; Verbeke S; Annala M; Brochez L; Van der Eecken K; Wyatt AW; Rottey S; Ost P
Eur Urol; 2019 May; 75(5):707-711. PubMed ID: 30665814
[TBL] [Abstract][Full Text] [Related]
15. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
[TBL] [Abstract][Full Text] [Related]
17. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial.
Zhu X; Liu W; Cao Y; Ju X; Zhao X; Jiang L; Ye Y; Zhang H
EClinicalMedicine; 2023 Jan; 55():101764. PubMed ID: 36471691
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
19. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
